Jeremie Calais

Title(s)HS Associate Clinical Professor, Molecular and Medical Pharmacology
SchoolMedicine
ORCID ORCID Icon0000-0002-8839-4379 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Paris-Diderot UniversityMD2010Medicine
    Paris-Sud UniversityMSc2017Biomedical Imaging
    Paris-Saclay UniversityPhD2023Medical Physics and Imaging

    Collapse Overview 
    Collapse Overview
    Nuclear medicine physician specialized in cancer imaging and theranostics.

    Associate Professor, Department of Molecular and Medical Pharmacology at UCLA
    Director, Theranostics Program, Ahmanson Translational Theranostics Division at UCLA
    Faculty Member of the Jonsson Comprehensive Cancer Center at UCLA.
    Faculty Member of the Institute of Urologic Oncology at UCLA.
    Faculty Member of the Physics and Biology in Medicine Graduate Program at UCLA
    Collapse Websites

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Featured Content 
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET-An International Multicenter Retrospective Study. J Nucl Med. 2025 Jan 03; 66(1):54-60. Unterrainer LM, Hope TA, Fendler WP, Grogan T, Ndlovu H, Armstrong W, Barbato F, Benz MR, Rettig MB, Kishan AU, Sathekge M, Herrmann K, Czernin J, Calais J. PMID: 39753363.
      View in: PubMed   Mentions:
    2. PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging. JAMA Netw Open. 2025 Jan 02; 8(1):e2452971. Holzgreve A, Armstrong WR, Clark KJ, Benz MR, Smith CP, Djaileb L, Gafita A, Thin P, Nickols NG, Kishan AU, Rettig MB, Reiter RE, Czernin J, Calais J. PMID: 39752157; PMCID: PMC11699533.
      View in: PubMed   Mentions:
    3. Clinical, Pathologic, and Imaging Variables Associated with Prostate Cancer Detection by PSMA PET/CT and Multiparametric MRI. J Nucl Med. 2024 Dec 03; 65(12):1923-1931. Sonni I, Weiner AB, Doddipalli S, Deol M, Ban D, Kim HO, Grogan T, Ahuja P, Barroso N, Zong Y, Soin P, Sisk A, Czernin J, Hsu W, Calais J, Reiter RE, Raman SS. PMID: 39477501.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study. J Nucl Med. 2024 Dec 03; 65(12):1952-1958. Huang RR, Zuo C, Mona CE, Holzgreve A, Morrissey C, Nelson PS, Brady L, True L, Sisk A, Czernin J, Calais J, Ye H. PMID: 39477498; PMCID: PMC11619584.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Challenges with 177Lu-PSMA-617 Radiopharmaceutical Therapy in Clinical Practice. J Nucl Med. 2024 Dec 03; 65(12):1851-1854. Jadvar H, Iravani A, Bodei L, Calais J. PMID: 39299786.
      View in: PubMed   Mentions:    Fields:    
    6. Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024. Cancer. 2024 Dec 01. Bryce AH, Agarwal N, Beltran H, Hussain MH, Sartor O, Shore N, Antonarakis ES, Armstrong AJ, Calais J, Carducci MA, Dorff TB, Efstathiou JA, Gleave M, Gomella LG, Higano C, Hope TA, Iagaru A, Morgans AK, Morris DS, Morris MJ, Petrylak DP, Reiter RE, Rettig MB, Ryan CJ, Sellinger SB, Spratt DE, Srinivas S, Tagawa ST, Taplin ME, Yu EY, Zhang T, McKay RR, Koo PJ, Crawford ED. PMID: 39616467.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    7. SNMMI Procedure Standard/EANM Practice Guideline for Fibroblast Activation Protein (FAP) PET. J Nucl Med. 2024 Nov 21. Hope TA, Calais J, Goenka AH, Haberkorn U, Konijnenberg M, McConathy J, Oprea-Lager DE, Trimnal L, Zan E, Herrmann K, Deroose CM. PMID: 39572227.
      View in: PubMed   Mentions:    Fields:    
    8. Molecular imaging of renal cell carcinomas: ready for prime time. Nat Rev Urol. 2024 Nov 14. Wu Q, Shao H, Zhai W, Huang G, Liu J, Calais J, Wei W. PMID: 39543358.
      View in: PubMed   Mentions:    Fields:    
    9. Corrigendum to "Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774)" [Eur Urol. 86(1) (2024) 52-60]. Eur Urol. 2024 Nov 08. Armstrong WR, Kishan AU, Booker KM, Grogan TR, Elashoff D, Lam EC, Clark KJ, Steinberg ML, Fendler WP, Hope TA, Nickols NG, Czernin J, Calais J. PMID: 39521695.
      View in: PubMed   Mentions:    Fields:    
    10. Correlation of FAPI PET Uptake with Immunohistochemistry in Explanted Lungs from Patients with Advanced Interstitial Lung Disease. J Nucl Med. 2024 Nov 01; 65(11):1789-1794. Hotta M, Kim GHJ, Rerkpichaisuth V, Teng PY, Armstrong WR, Carlucci G, Dahlbom M, Abtin F, Lari SM, Fishbein GA, Czernin J, Volkmann ER, Weigt SS, Calais J. PMID: 39362770.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    11. Efficacy and Toxicity of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data. J Nucl Med. 2024 Nov 01; 65(11):1740-1744. Murthy V, Voter AF, Nguyen K, Allen-Auerbach M, Chen L, Caputo S, Ledet E, Akerele A, Moradi Tuchayi A, Lawhn-Heath C, Wang T, Carducci MA, Pomper MG, Paller CJ, Czernin J, Solnes LB, Hope TA, Sartor O, Calais J, Gafita A. PMID: 39327018.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    12. Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy. J Nucl Med. 2024 Nov 01; 65(11):1666-1671. Calais J, Morris MJ, Kendi AT, Kalebasty AR, Tutrone R, Anderson MJ, Sartor O. PMID: 39362764; PMCID: PMC11533911.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    13. Novel Radiopharmaceuticals and Future of Theranostics in Genitourinary Cancers. Eur Urol. 2024 Oct 19. Sollini M, Calais J, Chiti A, Emmett L, Fanti S, Fendler W, Herrmann K, Hope TA, Sartor O, Shuch B, Tagawa S, Hofman MS. PMID: 39428326.
      View in: PubMed   Mentions:    Fields:    
    14. Phase 2 trial of PSMA PET CT versus planar bone scan and CT in prostate cancer patients progressing while on androgen deprivation therapy. Sci Rep. 2024 10 18; 14(1):24411. Nikitas J, Gafita A, Benz MR, Djaïleb L, Farolfi A, Hotta M, Sonni I, Alano R, Rettig M, Shen J, Armstrong W, Grogan T, Liu S, Czernin J, Calais J. PMID: 39420060; PMCID: PMC11487247.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    15. Clinical Responses to Prostate-specific Membrane Antigen Radioguided Salvage Lymphadenectomy for Prostate Cancer Recurrence: Results from a Prospective Exploratory Trial. Eur Urol Open Sci. 2024 Dec; 70:36-42. Weiner AB, Ells Z, Meyer C, Dahlbom M, Sennung D, Varughese D, Ludwig VB, Carlucci G, Grant R, Czernin J, Calais J, Reiter RE. PMID: 39483519; PMCID: PMC11525452.
      View in: PubMed   Mentions:
    16. Clinical Factors That Influence Repeat 68Ga-PSMA-11 PET/CT Scan Positivity in Patients with Recurrent Prostate Cancer Under Observation After a Negative 68Ga-PSMA-11 PET/CT Scan: A Single-Center Retrospective Study. J Nucl Med. 2024 Oct 01; 65(10):1571-1576. Thin P, Hotta M, Gafita A, Grogan T, Czernin J, Calais J, Sonni I. PMID: 39168522.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    17. Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naïve Prostate Cancer. Eur Urol. 2024 Dec; 86(6):579-587. Weiner AB, Agrawal R, Wang NK, Sonni I, Li EV, Arbet J, Zhang JJH, Proudfoot JA, Hong BH, Davicioni E, Kane N, Valle LF, Kishan AU, Pra AD, Ghadjar P, Sweeney CJ, Nickols NG, Karnes RJ, Shen J, Rettig MB, Czernin J, Ross AE, Lee Kiang Chua M, Schaeffer EM, Calais J, Boutros PC, Reiter RE. PMID: 39294048; PMCID: PMC11637967.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    18. Characterization of a gonadal vein Capillary Hemangioma by [68Ga]FAPI-46 and [18 F]FDG PET and immunohistochemistry: a potential pitfall of FAPI PET signal. Eur J Nucl Med Mol Imaging. 2024 Sep 04. Hotta M, Seyedroudbari A, Dry S, Girgis M, Calais J. PMID: 39227425.
      View in: PubMed   Mentions:    Fields:    
    19. Prostate-Specific Membrane Antigen PET/CT-Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2024 Sep 03; 65(9):1387-1394. Nikitas J, Castellanos Rieger A, Farolfi A, Seyedroudbari A, Kishan AU, Nickols NG, Steinberg ML, Valle LF, Rettig M, Czernin J, Calais J. PMID: 39089811.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    20. Standardized template for clinical reporting of PSMA PET/CT scans. Eur J Nucl Med Mol Imaging. 2024 Dec; 52(1):335-341. Esfahani SA, Morris MJ, Sartor O, Frydenberg M, Fanti S, Calais J, Vapiwala N. PMID: 39143250; PMCID: PMC11599343.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    21. [68Ga]Ga-FAPI-46 False-Positive Uptake After Chemotherapy in Nonseminomatous Germ Cell Tumor Metastatic Lesions. J Nucl Med. 2024 Aug 01; 65(8):1328-1329. Ludwig V, Maliha PG, Shen J, Tonnelet D, Raman S, Litwin MS, Calais J. PMID: 38664018.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    22. Dosimetry of [177Lu]Lu-PSMA-Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Metaanalysis. J Nucl Med. 2024 Aug 01; 65(8):1264-1271. Ells Z, Grogan TR, Czernin J, Dahlbom M, Calais J. PMID: 38960712; PMCID: PMC11294071.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    23. Transcriptomic Profiling of Primary Prostate Cancers and Nonlocalized Disease on Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: A Multicenter Retrospective Study. JCO Precis Oncol. 2024 Jul; 8:e2400161. Nikitas J, Subramanian K, Gozal NB, Ricaurte-Fajardo A, Li E, Proudfoot JA, Davicioni E, Marciscano AE, Osborne JR, Barbieri CE, Armstrong WR, Smith CP, Valle LF, Steinberg ML, Boutros PC, Nickols NG, Rettig MB, Reiter R, Weiner AB, Calais J, Czernin J, Ross AE, Kim EH, Nagar H, Kishan AU. PMID: 39013135.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    24. Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial). J Nucl Med. 2024 Jul 01; 65(7):1076-1079. Nikitas J, Lam E, Booker KA, Fendler WP, Eiber M, Hadaschik B, Herrmann K, Hirmas N, Lanzafame H, Stuschke M, Czernin J, Steinberg ML, Nickols NG, Kishan AU, Calais J. PMID: 38664019; PMCID: PMC11218723.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    25. RECIP 1.0 Predicts Progression-Free Survival After [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2024 Jun 03; 65(6):917-922. Gafita A, Djaileb L, Rauscher I, Fendler WP, Hadaschik B, Rowe SP, Herrmann K, Solnes LB, Calais J, Rettig MB, Weber M, Farolfi A, Benz MR, Eiber M. PMID: 38637143.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    26. Beyond Prostate Imaging Reporting and Data System: Combining Magnetic Resonance Imaging Prostate Imaging Reporting and Data System and Prostate-Specific Membrane Antigen-Positron Emission Tomography/Computed Tomography PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate Cancer. J Urol. 2024 Aug; 212(2):299-309. Emmett L, Papa N, Hope TA, Fendler W, Calais J, Burger I, Eiber M, Barbato F, Moon D, Counter W, John N, Xue A, Franklin A, Thompson J, Rasiah K, Frydenberg M, Yaxley J, Buteau J, Agrawal S, Ho B, Nguyen A, Liu V, Lee J, Woo H, Hsiao E, Sutherland T, Perry E, Stricker P, Hofman MS, Kasivisvanathan V, Roberts M, Murphy D. PMID: 38758680.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    27. FAPI PET uptake patterns after invasive medical interventions: a single center retrospective analysis. Eur J Nucl Med Mol Imaging. 2024 Sep; 51(11):3373-3385. Maliha PG, Hotta M, Farolfi A, Grogan T, Alano R, Limon A, Lam E, Carlucci G, Bahri S, Salavati A, Benz M, Silverman D, Gupta P, Quon A, Allen-Auerbach M, Czernin J, Calais J. PMID: 38750372.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    28. PSMA PET/CT Dual-Time-Point Imaging: Nice to Have or Need to Have? J Nucl Med. 2024 May 01; 65(5):818-819. Unterrainer LM, Ruchalski K, Allen-Auerbach MS, Calais J, Benz MR. PMID: 38176724.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    29. [68Ga]Ga-FAPI-46 PET in a Borderline Ovarian Tumor. J Nucl Med. 2024 May 01; 65(5):820-821. Unterrainer LM, Memarzadeh S, Moatamed NA, Benz MR, Czernin J, Calais J. PMID: 38212069.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    30. Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2. JU Open Plus. 2024 Apr; 2(4). Bryce AH, Crawford ED, Agarwal N, Hussain MH, Beltran H, Cooperberg MR, Petrylak DP, Shore N, Spratt DE, Tagawa ST, Antonarakis ES, Aparicio AM, Armstrong AJ, Boike TP, Calais J, Carducci MA, Chapin BF, Cookson MS, Davis JW, Dorff T, Eggener SE, Feng FY, Gleave M, Higano C, Iagaru A, Morgans AK, Morris M, Murray KS, Poage W, Rettig MB, Sartor O, Scher HI, Sieber P, Small E, Srinivas S, Yu EY, Zhang T, Koo PJ. PMID: 38774467; PMCID: PMC11107999.
      View in: PubMed   Mentions: 1  
    31. Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1. JU Open Plus. 2024 Apr; 2(4). Crawford ED, Bryce AH, Hussain MH, Agarwal N, Beltran H, Cooperberg MR, Petrylak DP, Shore N, Spratt DE, Tagawa ST, Antonarakis ES, Aparicio AM, Armstrong AJ, Boike TP, Calais J, Carducci MA, Chapin BF, Cookson MS, Davis JW, Dorff T, Eggener SE, Feng FY, Gleave M, Higano C, Iagaru A, Morgans AK, Morris M, Murray KS, Poage W, Rettig MB, Sartor O, Scher HI, Sieber P, Small E, Srinivas S, Yu EY, Zhang T, Koo PJ. PMID: 38774466; PMCID: PMC11108024.
      View in: PubMed   Mentions: 1  
    32. Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial. Eur Urol. 2024 Jun; 85(6):517-520. Nikitas J, Rettig M, Shen J, Reiter R, Lee A, Steinberg ML, Valle LF, Sachdeva A, Romero T, Calais J, Czernin J, Nickols NG, Kishan AU. PMID: 38494380; PMCID: PMC11386258.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    33. Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study. Eur Urol. 2024 Jun; 85(6):511-516. Weber M, Fendler WP, Ravi Kumar AS, Calais J, Czernin J, Ilhan H, Saad F, Kretschmer A, Hekimsoy T, Brookman-May SD, Mundle SD, Small EJ, Smith MR, Perez PM, Hope TA, Herrmann K, Hofman MS, Eiber M, Hadaschik BA. PMID: 38490855.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    34. Differences and Common Ground in 177Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers. J Nucl Med. 2024 Mar 01; 65(3):438-445. Farolfi A, Armstrong WR, Djaileb L, Gafita A, Hotta M, Allen-Auerbach M, Unterrainer LM, Fendler WP, Rettig M, Eiber M, Hofman MS, Hadaschik B, Herrmann K, Czernin J, Calais J, Benz MR. PMID: 38238041.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    35. The Potential Contribution of Radiopharmaceutical Therapies in Managing Oligometastatic Disease. J Nucl Med. 2024 Feb 15. Kishan AU, Siva S, Hofman MS, Nagarajah J, Kiess AP, Tran P, Calais J. PMID: 38360048.
      View in: PubMed   Mentions: 1     Fields:    
    36. Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774). Eur Urol. 2024 Jul; 86(1):52-60. Armstrong WR, Kishan AU, Booker KM, Grogan TR, Elashoff D, Lam EC, Clark KJ, Steinberg ML, Fendler WP, Hope TA, Nickols NG, Czernin J, Calais J. PMID: 38290964.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    37. Prostate-Specific Membrane Antigen: Gateway to Management of Advanced Prostate Cancer. Annu Rev Med. 2024 Jan 29; 75:49-66. Unterrainer LM, Calais J, Bander NH. PMID: 38285513.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    38. Impact of PSMA PET on Prostate Cancer Management. Curr Treat Options Oncol. 2024 02; 25(2):191-205. Weiner AB, Agrawal R, Valle LF, Sonni I, Kishan AU, Rettig MB, Raman SS, Calais J, Boutros PC, Reiter RE. PMID: 38270802; PMCID: PMC11034977.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    39. Characterizing Normal Variant [68Ga]Ga-FAPI-46 Uptake in the Epididymis. J Nucl Med. 2024 01 02; 65(1):59-62. Maliha PG, Hotta M, Czernin J, Calais J. PMID: 37945382.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    40. Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database. J Nucl Med. 2024 01 02; 65(1):94-99. Emmett L, Papa N, Counter W, Calais J, Barbato F, Burger I, Eiber M, Roberts MJ, Agrawal S, Franklin A, Xue A, Rasiah K, John N, Moon D, Frydenberg M, Yaxley J, Stricker P, Wong K, Coughlin G, Gianduzzo T, Kua B, Ho B, Nguyen A, Liu V, Lee J, Hsiao E, Sutherland T, Perry E, Fendler WP, Hope TA. PMID: 38050155.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    41. ACR-ACNM-ARS-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radiopharmaceuticals. Am J Clin Oncol. 2024 04 01; 47(4):169-176. Wallner PE, Yoo DC, Calais J, Escorcia FE, Mari Aparici C, Michalski J, Morris M, Morris ZS, Pryma D, Rabatic BM, Sharma N, Vapiwala N, Ghesani MV, Subramaniam RM, Small W, Schechter NR. PMID: 38131352.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    42. Effects of novel androgen receptor signaling inhibitors on PSMA PET signal intensity in patients with castrate-resistant prostate cancer: a prospective exploratory serial imaging study. EJNMMI Res. 2023 Oct 30; 13(1):95. Sonni I, Gafita A, Unterrainer LM, Alano RM, Lira S, Shen J, Drakaki A, Grogan T, Rettig MB, Czernin J, Calais J. PMID: 37902861; PMCID: PMC10616012.
      View in: PubMed   Mentions: 1  
    43. Tandem Isotope Therapy with 225Ac- and 177Lu-PSMA-617 in a Murine Model of Prostate Cancer. J Nucl Med. 2023 11; 64(11):1772-1778. Meyer C, Stuparu A, Lueckerath K, Calais J, Czernin J, Slavik R, Dahlbom M. PMID: 37797974; PMCID: PMC10626377.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimals
    44. Associations of quantitative whole-body PSMA-PET metrics with PSA progression status under long-term androgen deprivation therapy in prostate cancer patients: a retrospective single-center study. Eur J Hybrid Imaging. 2023 Oct 02; 7(1):18. Murthy V, Appiah-Kubi E, Nguyen K, Thin P, Hotta M, Shen J, Drakaki A, Rettig M, Gafita A, Calais J, Sonni I. PMID: 37779132; PMCID: PMC10542625.
      View in: PubMed   Mentions:
    45. Impact of 68Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers. J Nucl Med. 2023 11; 64(11):1712-1720. Koerber SA, Röhrich M, Walkenbach L, Liermann J, Choyke PL, Fink C, Schroeter C, Spektor AM, Herfarth K, Walle T, Calais J, Kauczor HU, Jaeger D, Debus J, Haberkorn U, Giesel FL. PMID: 37678928; PMCID: PMC10626373.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    46. Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with 177Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis. J Nucl Med. 2023 11; 64(11):1737-1743. Murthy V, Gafita A, Thin P, Nguyen K, Grogan T, Shen J, Drakaki A, Rettig M, Czernin J, Calais J. PMID: 37678927.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    47. Do Bone Scans Overstage Disease Compared with PSMA PET at Initial Staging? An International Multicenter Retrospective Study with Masked Independent Readers. J Nucl Med. 2023 11; 64(11):1744-1747. Hope TA, Benz M, Jiang F, Thompson D, Barbato F, Juarez R, Hernandez Pampaloni M, Allen-Auerbach M, Gupta P, Fendler WP, Calais J. PMID: 37591547.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    48. Redesigned Curricula, Stringent Licensing Criteria, and Integrated Independence Are Conditions for a Bright Future for Nuclear Medicine in the United States. J Nucl Med. 2023 Sep; 64(9):1359-1360. Czernin J, Calais J. PMID: 37562803.
      View in: PubMed   Mentions:    Fields:    
    49. Presurgical 68Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial. Eur Urol. 2023 12; 84(6):588-596. Djaïleb L, Armstrong WR, Thompson D, Gafita A, Farolfi A, Rajagopal A, Grogan TR, Nguyen K, Benz MR, Hotta M, Barbato F, Ceci F, Schwarzenböck SM, Unterrainer M, Zacho HD, Juarez R, Cooperberg M, Carroll P, Washington S, Reiter RE, Eiber M, Herrmann K, Fendler WP, Czernin J, Hope TA, Calais J. PMID: 37482512.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    50. 68Ga-FAPI-46 PET/CT Tracer Uptake in CT-diagnosed Intra-Abdominal Fat Necrosis. Radiol Imaging Cancer. 2023 07; 5(4):e230026. Maliha PG, Allen-Auerbach M, Hotta M, Calais J. PMID: 37389447; PMCID: PMC10413291.
      View in: PubMed   Mentions:    Fields:    
    51. Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate Cancer. Radiology. 2023 07; 308(1):e222148. Gafita A, Djaileb L, Rauscher I, Fendler WP, Hadaschik B, Rowe SP, Herrmann K, Calais J, Rettig M, Eiber M, Weber M, Benz MR, Farolfi A. PMID: 37432081; PMCID: PMC10374938.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    52. [68Ga]Ga-FAPI-46 PET for Visualization of Postinfarction Renal Fibrosis. J Nucl Med. 2023 10; 64(10):1660-1661. Unterrainer LM, Sisk AE, Czernin J, Shuch BM, Calais J, Hotta M. PMID: 37321822.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    53. PSMA-Negative Lesion Progression Under 177Lu-PSMA Radioligand Therapy. J Nucl Med. 2023 09; 64(9):1502-1503. Murthy V, Allen-Auerbach M, Lam R, Owen D, Czernin J, Calais J. PMID: 37321828.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    54. Focal therapy of prostate cancer: Assessment with prostate-specific membrane antigen (PSMA) imaging. Urol Case Rep. 2023 Sep; 50:102461. Topoozian M, Calais J, Felker E, Sisk A, Gonzalez S, Lee SJ, Marks LS. PMID: 37358989; PMCID: PMC10285561.
      View in: PubMed   Mentions: 1  
    55. Fibroblast Activation Protein Expression in Sarcomas. Sarcoma. 2023; 2023:2480493. Crane JN, Graham DS, Mona CE, Nelson SD, Samiei A, Dawson DW, Dry SM, Masri MG, Crompton JG, Benz MR, Czernin J, Eilber FC, Graeber TG, Calais J, Federman NC. PMID: 37333052; PMCID: PMC10275689.
      View in: PubMed   Mentions: 2  
    56. SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy. J Nucl Med. 2023 09; 64(9):1417-1423. Hope TA, Antonarakis ES, Bodei L, Calais J, Iravani A, Jacene H, Koo PJ, Morgans AK, Osborne JR, Tagawa ST, Taplin ME, Sartor O, Morris MJ. PMID: 37290800.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    57. Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023 06; 24(6):597-610. Fizazi K, Herrmann K, Krause BJ, Rahbar K, Chi KN, Morris MJ, Sartor O, Tagawa ST, Kendi AT, Vogelzang N, Calais J, Nagarajah J, Wei XX, Koshkin VS, Beauregard JM, Chang B, Ghouse R, DeSilvio M, Messmann RA, de Bono J. PMID: 37269841; PMCID: PMC10641914.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    58. Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2023 07; 50(9):2830-2845. Kratochwil C, Fendler WP, Eiber M, Hofman MS, Emmett L, Calais J, Osborne JR, Iravani A, Koo P, Lindenberg L, Baum RP, Bozkurt MF, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy FM, Oyen WJG, Rahbar K, Schoder H, Virgolini I, Bodei L, Fanti S, Haberkorn U, Hermann K. PMID: 37246997; PMCID: PMC10317889.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    59. Obstructive Sialadenitis from Oral Squamous Cell Carcinoma: [68Ga]Ga-FAPI-46 PET-Positive and [18F]FDG PET-Negative. J Nucl Med. 2023 11; 64(11):1839-1840. Maliha PG, Mendelsohn AH, Czernin J, Howard T, Calais J, Hotta M. PMID: 37230532.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    60. A VISION Substudy of Reader Agreement on 68Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177Lu-PSMA-617 Radioligand Therapy. J Nucl Med. 2023 08; 64(8):1259-1265. Kuo PH, Yoo DC, Avery R, Seltzer M, Calais J, Nagarajah J, Weber WA, Fendler WP, Hofman MS, Krause BJ, Brackman M, Kpamegan E, Ghebremariam S, Benson T, Catafau AM, Kendi AT. PMID: 37230533; PMCID: PMC10394308.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    61. Editorial Comment. J Urol. 2023 08; 210(2):299-311. Eifer M, Hope TA, Calais J, Hofman MS. PMID: 37203346.
      View in: PubMed   Mentions:    Fields:    
    62. FAPI PET Signal in Hibernoma Reflects FAP Expression in Tumor Vasculature Cells. Clin Nucl Med. 2023 Jul 01; 48(7):e353-e355. Hotta M, Mona CE, Crompton JG, Armstrong WR, Gafita A, Nelson SD, Eilber FC, Dawson DW, Calais J, Benz MR. PMID: 37146173.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    63. Looking at the Future of Prostate Cancer Treatment: A Conversation Between Michael Morris, Jeremie Calais, and Johannes Czernin. J Nucl Med. 2023 05; 64(5):678-681. Morris MJ, Calais J, Czernin J. PMID: 37055221.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    64. PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [177Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study. J Nucl Med. 2023 07; 64(7):1024-1029. Hotta M, Gafita A, Murthy V, Benz MR, Sonni I, Burger IA, Eiber M, Emmett L, Farolfi A, Fendler WP, Weber MM, Hofman MS, Hope TA, Kratochwil C, Czernin J, Calais J. PMID: 36997329.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    65. Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). Eur Urol. 2023 05; 83(5):405-412. Seifert R, Emmett L, Rowe SP, Herrmann K, Hadaschik B, Calais J, Giesel FL, Reiter R, Maurer T, Heck M, Gafita A, Morris MJ, Fanti S, Weber WA, Hope TA, Hofman MS, Fendler WP, Eiber M. PMID: 36935345.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    66. Transcriptomic Heterogeneity in High-risk Prostate Cancer and Implications for Extraprostatic Disease at Presentation on Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol Oncol. 2023 04; 6(2):224-227. Smith CP, Proudfoot JA, Boutros PC, Reiter RE, Valle L, Rettig MB, Nickols NG, Feng FY, Nguyen PL, Nagar H, Spratt DE, Attard G, Weiner A, Weidhaas JB, Calais J, Ma TM, Davicioni E, Xiang M, Kishan AU. PMID: 36870853.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    67. LUNAR: a randomized Phase 2 study of 177 Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (clinical trial protocol). BJU Int. 2023 07; 132(1):65-74. Ma TM, Czernin J, Felix C, Alano R, Wilhalme H, Valle L, Steinberg ML, Dahlbom M, Reiter RE, Rettig MB, Cao M, Calais J, Kishan AU. PMID: 36797449.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    68. Patterns of Failure in Men With Radiorecurrent Prostate Cancer: A Post Hoc Analysis of 3 Prospective Gallium 68 Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Trials. Int J Radiat Oncol Biol Phys. 2023 08 01; 116(5):1079-1084. Smith CP, Xiang M, Armstrong WR, Nickols NG, Steinberg ML, Reiter RE, Rettig M, Weiner AB, Shen J, Valle L, Czernin J, Calais J, Kishan AU. PMID: 36863416.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    69. The 177Lu-PSMA-617 (Pluvicto) Supply Problem Will Be Solved by Competition. J Nucl Med. 2023 03; 64(3):343. Czernin J, Calais J. PMID: 36863780.
      View in: PubMed   Mentions: 1     Fields:    
    70. Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer. Cancer Treat Rev. 2023 Apr; 115:102524. Calais J, Eulau SM, Gardner L, Hauke RJ, Kendi AT, Shore ND, Zhao S. PMID: 36933329.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    71. 68Ga-PSMA PET/CT-Based Atlas for Prostate Bed Recurrence After Radical Prostatectomy: Clinical Implications for Salvage Radiation Therapy Contouring Guidelines. J Nucl Med. 2023 06; 64(6):902-909. Sonni I, Dal Pra A, O'Connell DP, Ells Z, Benz M, Nguyen K, Yoon SM, Deng J, Smith C, Grogan T, Nickols NG, Cao M, Kishan AU, Calais J. PMID: 36759200; PMCID: PMC10241009.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    72. SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors. J Nucl Med. 2023 02; 64(2):204-210. Hope TA, Allen-Auerbach M, Bodei L, Calais J, Dahlbom M, Dunnwald LK, Graham MM, Jacene HA, Heath CL, Mittra ES, Wright CL, Fendler WP, Herrmann K, Taïeb D, Kjaer A. PMID: 36725249.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    73. Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer. J Nucl Med. 2023 06; 64(6):869-872. Gudenkauf LM, Chavez MN, Maconi ML, Geiss C, Seyedroudbari A, Thin P, Hoogland AI, Nguyen K, Murthy V, Armstrong WR, Komrokji K, Oswald LB, Jim HSL, El-Haddad G, Fendler WP, Herrmann K, Cella D, Czernin J, Hofman MS, Dicker AP, Calais J, Tagawa ST, Gonzalez BD. PMID: 36635088; PMCID: PMC10241017.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    74. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023 04; 50(5):1466-1486. Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, Cho SY, Fanti S, Giesel FL, Goffin K, Haberkorn U, Jacene H, Koo PJ, Kopka K, Krause BJ, Lindenberg L, Marcus C, Mottaghy FM, Oprea-Lager DE, Osborne JR, Piert M, Rowe SP, Schöder H, Wan S, Wester HJ, Hope TA, Herrmann K. PMID: 36604326; PMCID: PMC10027805.
      View in: PubMed   Mentions: 70     Fields:    Translation:Humans
    75. Incidental Focal 68Ga-FAPI-46 Uptake in a Urachal Remnant: A Potential Pitfall Mimicking a Malignant Peritoneal Lesion. J Nucl Med. 2023 06; 64(6):992. Maliha PG, Jafarvard M, Czernin J, Calais J, Hotta M. PMID: 36581376.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    76. Exploring new frontiers in prostate cancer research: Report from the 2022 Coffey-Holden prostate cancer academy meeting. Prostate. 2023 02; 83(3):207-226. Miyahira AK, Hawley JE, Adelaiye-Ogala R, Calais J, Nappi L, Parikh R, Seibert TM, Wasmuth EV, Wei XX, Pienta KJ, Soule HR. PMID: 36443902.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    77. Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225. EJNMMI Res. 2022 Oct 01; 12(1):65. Meyer C, Prasad V, Stuparu A, Kletting P, Glatting G, Miksch J, Solbach C, Lueckerath K, Nyiranshuti L, Zhu S, Czernin J, Beer AJ, Slavik R, Calais J, Dahlbom M. PMID: 36182983; PMCID: PMC9526774.
      View in: PubMed   Mentions: 5  
    78. Non-oncologic incidental uptake on FAPI PET/CT imaging. Br J Radiol. 2023 Feb; 96(1142):20220463. Hotta M, Rieger AC, Jafarvand MG, Menon N, Farolfi A, Benz MR, Calais J. PMID: 35776566; PMCID: PMC9975522.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    79. More Unacceptable Denials: Now It's PSMA-Targeted PET/CT Imaging. J Nucl Med. 2022 07; 63(7):969-970. Czernin J, Adams T, Calais J. PMID: 35772954.
      View in: PubMed   Mentions: 3     Fields:    
    80. Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria. Eur J Nucl Med Mol Imaging. 2022 Oct; 49(12):4271-4281. Gafita A, Rauscher I, Fendler WP, Murthy V, Hui W, Armstrong WR, Herrmann K, Weber WA, Calais J, Eiber M, Weber M, Benz MR. PMID: 35767071.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    81. How Many Theranostics Centers Will We Need in the United States? J Nucl Med. 2022 06; 63(6):805-806. Czernin J, Calais J. PMID: 35649664.
      View in: PubMed   Mentions: 5     Fields:    
    82. Tumor Sink Effect: Myth or Reality? J Nucl Med. 2022 07; 63(7):1124. Gafita A, Calais J, Fendler WP, Eiber M. PMID: 35483966.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    83. Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study. J Nucl Med. 2022 11; 63(11):1651-1658. Gafita A, Rauscher I, Weber M, Hadaschik B, Wang H, Armstrong WR, Tauber R, Grogan TR, Czernin J, Rettig MB, Herrmann K, Calais J, Weber WA, Benz MR, Fendler WP, Eiber M. PMID: 35422442; PMCID: PMC9635677.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    84. Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMA and Beyond. Am Soc Clin Oncol Educ Book. 2022 Apr; 42:1-17. Gafita A, Marcus C, Kostos L, Schuster DM, Calais J, Hofman MS. PMID: 35609224.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    85. PSMA PET in Prostate Cancer-A Biomarker or a Surrogate End Point?-Reply. JAMA Oncol. 2022 04 01; 8(4):1. Hope TA, Calais J. PMID: 35175289.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    86. Outcome of Patients with PSMA PET/CT Screen Failure by VISION Criteria and Treated with 177Lu-PSMA Therapy: A Multicenter Retrospective Analysis. J Nucl Med. 2022 10; 63(10):1484-1488. Hotta M, Gafita A, Czernin J, Calais J. PMID: 35273096.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    87. Imaging Prostate Cancer: Clinical Utility of Prostate-Specific Membrane Antigen. J Urol. 2022 Apr; 207(4):769-778. Kuppermann D, Calais J, Marks LS. PMID: 35085002.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansPHPublic Health
    88. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. JAMA Netw Open. 2021 12 01; 4(12):e2138550. Xiang M, Ma TM, Savjani R, Pollom EL, Karnes RJ, Grogan T, Wong JK, Motterle G, Tosoian JJ, Trock BJ, Klein EA, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Levin-Epstein R, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Huland H, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Alam R, Schwen Z, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Chong N, Kupelian PA, Rettig MB, Zaorsky NG, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Tilki D, Czernin J, Gafita A, Romero T, Calais J, Kishan AU. PMID: 34902034; PMCID: PMC8669522.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    89. Refining the definition of biochemical failure in the era of stereotactic body radiation therapy for prostate cancer: The Phoenix definition and beyond. Radiother Oncol. 2022 01; 166:1-7. Ma TM, Roy S, Wu X, Mantz C, Fuller D, Miszczyk L, Napieralska A, Namysl-Kaletka A, Bagshaw HP, Buyyounouski MK, Glicksman R, Loblaw DA, Katz A, Upadhyaya SK, Nickols N, Steinberg ML, Philipson R, Aghdam N, Suy S, Pepin A, Collins SP, Boutros P, Rettig MB, Calais J, Wang M, Zaorsky N, Kishan AU. PMID: 34774650.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    90. Correlation of 68Ga-FAPi-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of a Prospective Translational Exploratory Study. J Nucl Med. 2022 07; 63(7):1021-1026. Mona CE, Benz MR, Hikmat F, Grogan TR, Lueckerath K, Razmaria A, Riahi R, Slavik R, Girgis MD, Carlucci G, Kelly KA, French SW, Czernin J, Dawson DW, Calais J. PMID: 34740953; PMCID: PMC9258565.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCTClinical Trials
    91. PSMA Expression Assessed by PET Imaging Is a Required Biomarker for Selecting Patients for Any PSMA-Targeted Therapy. J Nucl Med. 2021 Nov; 62(11):1489-1491. Calais J, Czernin J. PMID: 34725231; PMCID: PMC8612346.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    92. Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial. JAMA Oncol. 2021 Nov 01; 7(11):1635-1642. Hope TA, Eiber M, Armstrong WR, Juarez R, Murthy V, Lawhn-Heath C, Behr SC, Zhang L, Barbato F, Ceci F, Farolfi A, Schwarzenböck SM, Unterrainer M, Zacho HD, Nguyen HG, Cooperberg MR, Carroll PR, Reiter RE, Holden S, Herrmann K, Zhu S, Fendler WP, Czernin J, Calais J. PMID: 34529005; PMCID: PMC8446902.
      View in: PubMed   Mentions: 99     Fields:    Translation:HumansCTClinical Trials
    93. Head-to-Head Comparison of 68Ga-PSMA-11 PET/CT and mpMRI with a Histopathology Gold Standard in the Detection, Intraprostatic Localization, and Determination of Local Extension of Primary Prostate Cancer: Results from a Prospective Single-Center Imaging Trial. J Nucl Med. 2022 06; 63(6):847-854. Sonni I, Felker ER, Lenis AT, Sisk AE, Bahri S, Allen-Auerbach M, Armstrong WR, Suvannarerg V, Tubtawee T, Grogan T, Elashoff D, Eiber M, Raman SS, Czernin J, Reiter RE, Calais J. PMID: 34649942; PMCID: PMC9157724.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    94. PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study. J Nucl Med. 2022 Jan; 63(1):76-80. Ferdinandus J, Fendler WP, Farolfi A, Washington S, Mohamad O, Pampaloni MH, Scott PJH, Rodnick M, Viglianti BL, Eiber M, Herrmann K, Czernin J, Armstrong WR, Calais J, Hope TA, Piert M. PMID: 34620731; PMCID: PMC8717195.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    95. 18F-FLT PET/CT as a Prognostic Imaging Biomarker of Disease-Specific Survival in Patients with Primary Soft-Tissue Sarcoma. J Nucl Med. 2022 05; 63(5):708-712. Crompton JG, Armstrong WR, Eckardt MA, Seyedroudbari A, Tap WD, Dry SM, Abt ER, Calais J, Herrmann K, Czernin J, Eilber FC, Benz MR. PMID: 34593596; PMCID: PMC9051595.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    96. Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. J Nucl Med. 2022 Jan; 63(1):59-68. Jadvar H, Calais J, Fanti S, Feng F, Greene KL, Gulley JL, Hofman M, Koontz BF, Lin DW, Morris MJ, Rowe SP, Royce TJ, Salami S, Savir-Baruch B, Srinivas S, Hope TA. PMID: 34593595; PMCID: PMC8717184.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    97. High 68 Ga-FAPI-46 uptake in a pulmonary necrotizing granuloma in a patient with subcutaneous lipoma. Eur J Nucl Med Mol Imaging. 2022 02; 49(3):1088-1089. Hotta M, Benz MR, Allen-Auerbach MS, Crompton JG, Roth MD, Eilber FC, Calais J. PMID: 34546387.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    98. Salvage therapy for prostate cancer after radical prostatectomy. Nat Rev Urol. 2021 11; 18(11):643-668. Zaorsky NG, Calais J, Fanti S, Tilki D, Dorff T, Spratt DE, Kishan AU. PMID: 34363040.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    99. A Comprehensive Assessment of 68Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients. J Nucl Med. 2022 04; 63(4):567-572. Abghari-Gerst M, Armstrong WR, Nguyen K, Calais J, Czernin J, Lin D, Jariwala N, Rodnick M, Hope TA, Hearn J, Montgomery JS, Alva A, Reichert ZR, Spratt DE, Johnson TD, Scott PJH, Piert M. PMID: 34326126; PMCID: PMC8973291.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    100. 18F-FDG PET/CT Imaging Biomarkers for Early and Late Evaluation of Response to First-Line Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma. J Nucl Med. 2022 Feb; 63(2):199-204. Benz MR, Armstrong WR, Ceci F, Polverari G, Donahue TR, Wainberg ZA, Quon A, Auerbach M, Girgis MD, Herrmann K, Czernin J, Calais J. PMID: 34272317.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    101. Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312). J Nucl Med. 2021 Oct; 62(10):1447-1456. Calais J, Czernin J, Thin P, Gartmann J, Nguyen K, Armstrong WR, Allen-Auerbach M, Quon A, Bahri S, Gupta P, Gardner L, Dahlbom M, He B, Esfandiari R, Ranganathan D, Herrmann K, Eiber M, Fendler WP, Delpassand E. PMID: 34272322; PMCID: PMC8724902.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    102. Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncol. 2021 08; 22(8):1115-1125. Gafita A, Calais J, Grogan TR, Hadaschik B, Wang H, Weber M, Sandhu S, Kratochwil C, Esfandiari R, Tauber R, Zeldin A, Rathke H, Armstrong WR, Robertson A, Thin P, D'Alessandria C, Rettig MB, Delpassand ES, Haberkorn U, Elashoff D, Herrmann K, Czernin J, Hofman MS, Fendler WP, Eiber M. PMID: 34246328.
      View in: PubMed   Mentions: 77     Fields:    Translation:Humans
    103. 177Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine. J Nucl Med. 2021 Aug 01; 62(8):1025-1026. Czernin J, Calais J. PMID: 34330737.
      View in: PubMed   Mentions: 6     Fields:    
    104. Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients. Eur J Nucl Med Mol Imaging. 2021 12; 48(13):4377-4385. Giesel FL, Kratochwil C, Schlittenhardt J, Dendl K, Eiber M, Staudinger F, Kessler L, Fendler WP, Lindner T, Koerber SA, Cardinale J, Sennung D, Roehrich M, Debus J, Sathekge M, Haberkorn U, Calais J, Serfling S, Buck AL. PMID: 34137945; PMCID: PMC8566651.
      View in: PubMed   Mentions: 78     Fields:    Translation:Humans
    105. Tumor Sink Effect in 68Ga-PSMA-11 PET: Myth or Reality? J Nucl Med. 2022 02; 63(2):226-232. Gafita A, Wang H, Robertson A, Armstrong WR, Zaum R, Weber M, Yagubbayli F, Kratochwil C, Grogan TR, Nguyen K, Navarro F, Esfandiari R, Rauscher I, Menze B, Elashoff D, Delpassand ES, Herrmann K, Czernin J, Hofman MS, Calais J, Fendler WP, Eiber M. PMID: 34049987; PMCID: PMC8805781.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    106. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort. J Nucl Med. 2021 Oct; 62(10):1440-1446. Calais J, Gafita A, Eiber M, Armstrong WR, Gartmann J, Thin P, Nguyen K, Lok V, Gosa L, Grogan T, Esfandiari R, Allen-Auerbach M, Quon A, Bahri S, Gupta P, Gardner L, Ranganathan D, Slavik R, Dahlbom M, Herrmann K, Delpassand E, Fendler WP, Czernin J. PMID: 34016732; PMCID: PMC8724893.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    107. Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol. BMC Cancer. 2021 May 07; 21(1):512. Calais J, Zhu S, Hirmas N, Eiber M, Hadaschik B, Stuschke M, Herrmann K, Czernin J, Kishan AU, Nickols NG, Elashoff D, Fendler WP. PMID: 33962579; PMCID: PMC8103642.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    108. Reply to Alexa R. Meyer, Steven P. Rowe, and Nirmish Singla's Letter to the Editor re: Patrick D. McGillivray, Daiki Ueno, Aydin Pooli, et al. Distinguishing Benign Renal Tumors with an Oncocytic Gene Expression (ONEX) Classifier. Eur Urol 2021;79:107-11. Integrating 99mTc-sestamibi and ONEX to Optimize Risk Stratification for Renal Masses. Eur Urol. 2021 07; 80(1):e22-e23. Shuch B, Raman S, Calais J. PMID: 33941405.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    109. 68Ga-FAPI-46 and 18F-FDG PET/CT in a patient with immune-related thyroiditis induced by immune checkpoint inhibitors. Eur J Nucl Med Mol Imaging. 2021 10; 48(11):3736-3737. Hotta M, Sonni I, Benz MR, Gafita A, Bahri S, Shuch BM, Yu R, Liu ST, Czernin J, Calais J. PMID: 33914106.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    110. Prostate-specific Membrane Antigen PET in Prostate Cancer. Radiology. 2021 05; 299(2):248-260. Lawhn-Heath C, Salavati A, Behr SC, Rowe SP, Calais J, Fendler WP, Eiber M, Emmett L, Hofman MS, Hope TA. PMID: 33787338.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    111. Accuracy of 18F-Fluorocholine PET for the Detection of Parathyroid Adenomas: Prospective Single-Center Study. J Nucl Med. 2021 Nov; 62(11):1511-1516. Hope TA, Graves CE, Calais J, Ehman EC, Johnson GB, Thompson D, Aslam M, Duh QY, Gosnell JE, Shen WT, Roman SA, Sosa JA, Kluijfhout WP, Seib CD, Villaneuva-Meyer JE, Pampaloni MH, Suh I. PMID: 33674400; PMCID: PMC8612343.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    112. Use and Impact of Positron Emission Tomography/Computed Tomography Prior to Salvage Radiation Therapy in Men with Biochemical Recurrence After Radical Prostatectomy: A Scoping Review. Eur Urol Oncol. 2021 06; 4(3):339-355. Valle L, Shabsovich D, de Meerleer G, Maurer T, Murphy DG, Nickols NG, Vapiwala N, Calais J, Kishan AU. PMID: 33637464.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    113. We Can Make a Difference: Investigator-driven Prostate-specific Membrane Antigen Radiotheranostics for Prostate Cancer. Eur Urol Focus. 2021 03; 7(2):227-228. Fendler WP, Calais J. PMID: 33612416.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    114. Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging. Eur Urol Oncol. 2022 02; 5(1):100-103. Ma TM, Gafita A, Shabsovich D, Juarez J, Grogan TR, Thin P, Armstrong W, Sonni I, Nguyen K, Lok V, Reiter RE, Rettig MB, Steinberg ML, Kupelian PA, Yang DD, Muralidhar V, Chu C, Feng F, Savjani R, Deng J, Parikh NR, Nickols NG, Elashoff D, Czernin J, Calais J, Kishan AU. PMID: 33602654; PMCID: PMC10262977.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    115. PSMA-targeted radiopharmaceutical therapy in patients with metastatic castration-resistant prostate cancer. Lancet. 2021 02 27; 397(10276):768-769. Hope TA, Calais J. PMID: 33581799.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    116. Oliver Sartor Talks with Thomas A. Hope, Jeremie Calais, and Wolfgang P. Fendler About FDA Approval of PSMA. J Nucl Med. 2021 02; 62(2):146-148. Sartor O, Hope TA, Calais J, Fendler WP. PMID: 33468543.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    117. Incidental Detection of Elastofibroma Dorsi With 68Ga-FAPI-46 and 18F-FDG PET/CT in a Patient With Esophageal Cancer. Clin Nucl Med. 2021 Feb 01; 46(2):e86-e87. Hayrapetian A, Girgis MD, Yanagawa J, French SW, Schelbert HR, Auerbach MS, Czernin J, Calais J. PMID: 32701818.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    118. The Impact of Monosodium Glutamate on 68Ga-PSMA-11 Biodistribution in Men with Prostate Cancer: A Prospective Randomized, Controlled Imaging Study. J Nucl Med. 2021 Sep 01; 62(9):1244-1251. Armstrong WR, Gafita A, Zhu S, Thin P, Nguyen K, Alano R, Lira S, Booker K, Gardner L, Grogan T, Elashoff D, Allen-Auerbach M, Dahlbom M, Czernin J, Calais J. PMID: 33509974; PMCID: PMC9364769.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    119. Update from PSMA-SRT Trial NCT03582774: A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron Emission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical Outcome. Eur Urol Focus. 2021 03; 7(2):238-240. Calais J, Armstrong WR, Kishan AU, Booker KM, Hope TA, Fendler WP, Elashoff D, Nickols NG, Czernin J. PMID: 33386288; PMCID: PMC8057677.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    120. Will FAPI PET/CT Replace FDG PET/CT in the Next Decade? Point-An Important Diagnostic, Phenotypic, and Biomarker Role. AJR Am J Roentgenol. 2021 02; 216(2):305-306. Calais J, Mona CE. PMID: 32755205.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    121. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). Eur Urol. 2021 09; 80(3):280-292. Valle LF, Lehrer EJ, Markovic D, Elashoff D, Levin-Epstein R, Karnes RJ, Reiter RE, Rettig M, Calais J, Nickols NG, Dess RT, Spratt DE, Steinberg ML, Nguyen PL, Davis BJ, Zaorsky NG, Kishan AU. PMID: 33309278; PMCID: PMC10262981.
      View in: PubMed   Mentions: 86     Fields:    Translation:Humans
    122. Radiation Dosimetry of 99mTc-PSMA I&S: A Single-Center Prospective Study. J Nucl Med. 2021 Aug 01; 62(8):1075-1081. Urbán S, Meyer C, Dahlbom M, Farkas I, Sipka G, Besenyi Z, Czernin J, Calais J, Pávics L. PMID: 33277398.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    123. Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer. J Nucl Med. 2021 Jul 01; 62(7):989-995. Stuparu AD, Capri JR, Meyer CAL, Le TM, Evans-Axelsson SL, Current K, Lennox M, Mona CE, Fendler WP, Calais J, Eiber M, Dahlbom M, Czernin J, Radu CG, Lückerath K, Slavik R. PMID: 33277393; PMCID: PMC8882874.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    124. [18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial. EJNMMI Res. 2020 Oct 15; 10(1):122. Polverari G, Ceci F, Passera R, Crane J, Du L, Li G, Fanti S, Bernthal N, Eilber FC, Allen-Auerbach M, Czernin J, Calais J, Federman N. PMID: 33063147; PMCID: PMC7561652.
      View in: PubMed   Mentions: 1  
    125. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study. Eur Urol Oncol. 2022 10; 5(5):544-552. Lenis AT, Pooli A, Lec PM, Sadun TY, Johnson DC, Lebacle C, Fendler WP, Eiber M, Czernin J, Reiter RE, Calais J. PMID: 32958451.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    126. The Impact of 18F-DCFPyL PET-CT Imaging on Initial Staging, Radiation, and Systemic Therapy Treatment Recommendations for Veterans With Aggressive Prostate Cancer. Adv Radiat Oncol. 2020 Nov-Dec; 5(6):1364-1369. Parikh NR, Tsai S, Bennett C, Lewis M, Sadeghi A, Lorentz W, Cheung M, Garraway I, Aronson W, Kishan AU, Bahri S, Vahidi K, Calais J, Ishimitsu D, Rettig M, Nickols NG, Jafari L. PMID: 33305100; PMCID: PMC7718503.
      View in: PubMed   Mentions: 1  
    127. Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. Prostate. 2020 11; 80(15):1273-1296. Miyahira AK, Pienta KJ, Babich JW, Bander NH, Calais J, Choyke P, Hofman MS, Larson SM, Lin FI, Morris MJ, Pomper MG, Sandhu S, Scher HI, Tagawa ST, Williams S, Soule HR. PMID: 32865839; PMCID: PMC8442561.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    128. False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial. Eur J Nucl Med Mol Imaging. 2021 02; 48(2):501-508. Fendler WP, Calais J, Eiber M, Simko JP, Kurhanewicz J, Santos RD, Feng FY, Reiter RE, Rettig MB, Nickols NG, Kishan AU, PSMA PET Reader Group, Slavik R, Carroll PR, Lawhn-Heath C, Herrmann K, Czernin J, Hope TA. PMID: 32808077; PMCID: PMC7835157.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    129. 68Ga-FAPi-46 diffuse bilateral breast uptake in a patient with cervical cancer after hormonal stimulation. Eur J Nucl Med Mol Imaging. 2021 03; 48(3):924-926. Sonni I, Lee-Felker S, Memarzadeh S, Quinn MM, Mona CE, Lückerath K, Czernin J, Calais J. PMID: 32651662.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    130. PSMA Expression in the Neovasculature Associated With Rectal Adenocarcinoma: A Potential Stromal Target for Nuclear Theranostics. Clin Nucl Med. 2020 Jul; 45(7):e309-e310. Sonni I, Caron J, Kishan AU, Muthusamy VR, Calais J. PMID: 32404709.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    131. Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study. Eur Urol. 2020 08; 78(2):148-154. Gafita A, Fendler WP, Hui W, Sandhu S, Weber M, Esfandiari R, Calais J, Rauscher I, Rathke H, Tauber R, Delpassand ES, Weber WA, Herrmann K, Czernin J, Eiber M, Hofman MS. PMID: 32532512.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    132. Correlation Between FDG Hotspots on Pre-radiotherapy PET/CT and Areas of HNSCC Local Relapse: Impact of Treatment Position and Images Registration Method. Front Med (Lausanne). 2020; 7:218. Truffault B, Bourhis D, Chaput A, Calais J, Robin P, Le Pennec R, Lucia F, Leclère JC, Gujral DM, Vera P, Salaün PY, Schick U, Abgral R. PMID: 32582727; PMCID: PMC7287148.
      View in: PubMed   Mentions: 2  
    133. Nuclear Medicine, Molecular Imaging, and Theranostics: The Future Is Bright. J Nucl Med Technol. 2020 Jun; 48(Suppl 1):82S-83S. Czernin J, Calais J. PMID: 32605963.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    134. PSMA-targeted Radiotracers versus 18F Fluciclovine for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis. Radiology. 2020 07; 296(1):44-55. Tan N, Oyoyo U, Bavadian N, Ferguson N, Mukkamala A, Calais J, Davenport MS. PMID: 32396045.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    135. Impact of 68Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial. J Nucl Med. 2020 12; 61(12):1793-1799. Fendler WP, Ferdinandus J, Czernin J, Eiber M, Flavell RR, Behr SC, Wu IK, Lawhn-Heath C, Pampaloni MH, Reiter RE, Rettig MB, Gartmann J, Murthy V, Slavik R, Carroll PR, Herrmann K, Calais J, Hope TA. PMID: 32358094; PMCID: PMC9364898.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCTClinical Trials
    136. FAP: The Next Billion Dollar Nuclear Theranostics Target? J Nucl Med. 2020 02; 61(2):163-165. Calais J. PMID: 31924719.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    137. Impact of 68Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study. J Nucl Med. 2020 08; 61(8):1153-1160. Sonni I, Eiber M, Fendler WP, Alano RM, Vangala SS, Kishan AU, Nickols N, Rettig MB, Reiter RE, Czernin J, Calais J. PMID: 31924715; PMCID: PMC7413232.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCTClinical Trials
    138. Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients. J Nucl Med. 2020 08; 61(8):1171-1177. Meyer C, Dahlbom M, Lindner T, Vauclin S, Mona C, Slavik R, Czernin J, Haberkorn U, Calais J. PMID: 31836685; PMCID: PMC7413240.
      View in: PubMed   Mentions: 82     Fields:    Translation:Humans
    139. Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PET. J Nucl Med. 2020 07; 61(7):1037-1042. Farolfi A, Ilhan H, Gafita A, Calais J, Barbato F, Weber M, Afshar-Oromieh A, Spohn F, Wetter A, Rischpler C, Hadaschik B, Pianori D, Fanti S, Haberkorn U, Eiber M, Herrmann K, Fendler WP. PMID: 31806773; PMCID: PMC7383079.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    140. Evaluation of SUV normalized by lean body mass (SUL) in 68Ga-PSMA11 PET/CT: a bi-centric analysis. EJNMMI Res. 2019 Dec 02; 9(1):103. Gafita A, Calais J, Franz C, Rauscher I, Wang H, Roberstson A, Czernin J, Weber WA, Eiber M. PMID: 31792771; PMCID: PMC6889088.
      View in: PubMed   Mentions: 6  
    141. Of Sheep and Wolves: Curtailing Coverage for Essential Imaging Tests Based on Flawed Use and Cost Arguments. J Nucl Med. 2019 12; 60(12):1657-1658. Czernin J, Allen-Auerbach M, Calais J. PMID: 31792126.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    142. What is the best PET target for early biochemical recurrence of prostate cancer?-Authors' reply. Lancet Oncol. 2019 11; 20(11):e609-e610. Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Fendler WP, Czernin J. PMID: 31674314.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    143. Total-Body 68Ga-PSMA-11 PET/CT for Bone Metastasis Detection in Prostate Cancer Patients: Potential Impact on Bone Scan Guidelines. J Nucl Med. 2020 03; 61(3):405-411. Pomykala KL, Czernin J, Grogan TR, Armstrong WR, Williams J, Calais J. PMID: 31541035; PMCID: PMC7067527.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    144. Reply by Authors. J Urol. 2019 12; 202(6):1181. Farolfi A, Gafita A, Calais J, Eiber M, Afshar-Oromieh A, Spohn F, Barbato F, Weber M, Ilhan H, Cervati V, Wetter A, Hadaschik B, Briganti A, Walz J, Pianori D, Fanti S, Haberkorn U, Herrmann K, Fendler WP. PMID: 31524577.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    145. The Future of Nuclear Medicine as an Independent Specialty. J Nucl Med. 2019 09; 60(Suppl 2):3S-12S. Czernin J, Sonni I, Razmaria A, Calais J. PMID: 31481589.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    146. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019 09; 20(9):1286-1294. Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan AU, Rettig MB, Reiter RE, Fendler WP, Czernin J. PMID: 31375469; PMCID: PMC7469487.
      View in: PubMed   Mentions: 157     Fields:    Translation:HumansCTClinical Trials
    147. Can the Injected Dose Be Reduced in 68Ga-PSMA-11 PET/CT While Maintaining High Image Quality for Lesion Detection? J Nucl Med. 2020 02; 61(2):189-193. Rauscher I, Fendler WP, Hope TA, Quon A, Nekolla SG, Calais J, Richter A, Haller B, Herrmann K, Weber WA, Czernin J, Eiber M. PMID: 31324710; PMCID: PMC8801954.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    148. Imaging of Prostate Specific Membrane Antigen Targeted Radiotracers for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis. J Urol. 2019 08; 202(2):231-240. Tan N, Bavadian N, Calais J, Oyoyo U, Kim J, Turkbey IB, Mena E, Davenport MS. PMID: 30829130.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    149. 68Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study. J Urol. 2019 12; 202(6):1174-1181. Farolfi A, Gafita A, Calais J, Eiber M, Afshar-Oromieh A, Spohn F, Barbato F, Weber M, Ilhan H, Cervati V, Wetter A, Hadaschik B, Briganti A, Walz J, Pianori D, Fanti S, Haberkorn U, Herrmann K, Fendler WP. PMID: 31233369.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    150. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol. 2019 Jun 01; 5(6):856-863. Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R, Small EJ, Slavik R, Carroll PR, Herrmann K, Czernin J, Hope TA. PMID: 30920593; PMCID: PMC6567829.
      View in: PubMed   Mentions: 279     Fields:    Translation:HumansCTClinical Trials
    151. Prostate Cancer Pulmonary Metastasis Presenting as a Ground-Glass Pulmonary Nodule on 68Ga-PSMA-11 PET/CT. Clin Nucl Med. 2019 05; 44(5):e353-e356. Lubin DJ, Holden SB, Rettig MB, Reiter RE, King CR, Lee JM, Wallace DW, Calais J. PMID: 30789399.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    152. 111In-Pentetreotide Scintigraphy Versus 68Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden. J Nucl Med. 2019 09; 60(9):1266-1269. Hope TA, Calais J, Zhang L, Dieckmann W, Millo C. PMID: 30850506; PMCID: PMC6735279.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCTClinical Trials
    153. Correction to: Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]. BMC Cancer. 2019 01 21; 19(1):97. Calais J, Czernin J, Fendler WP, Elashoff D, Nickols NG. PMID: 30665383; PMCID: PMC6341574.
      View in: PubMed   Mentions: 1     Fields:    
    154. Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]. BMC Cancer. 2019 Jan 07; 19(1):18. Calais J, Czernin J, Fendler WP, Elashoff D, Nickols NG. PMID: 30616601; PMCID: PMC6322287.
      View in: PubMed   Mentions: 41     Fields:    
    155. Delivering Radionuclide Therapies Requires Extensive Training and Competence: Send a Firm Message to the NRC and Your Representatives. J Nucl Med. 2019 01; 60(1):1-2. Razmaria A, Calais J, Czernin J. PMID: 30602593.
      View in: PubMed   Mentions:    Fields:    
    156. Metaanalysis of 68Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology. J Nucl Med. 2019 06; 60(6):786-793. Hope TA, Goodman JZ, Allen IE, Calais J, Fendler WP, Carroll PR. PMID: 30530831; PMCID: PMC6581235.
      View in: PubMed   Mentions: 91     Fields:    Translation:Humans
    157. The influence of PSA flare in mCRPC patients treated with alpha-emitting radiopharmaceuticals. Eur J Nucl Med Mol Imaging. 2018 12; 45(13):2253-2255. Ceci F, Polverari G, Calais J, Castellucci P. PMID: 30232540.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    158. Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer. EJNMMI Res. 2018 Oct 29; 8(1):96. Lückerath K, Wei L, Fendler WP, Evans-Axelsson S, Stuparu AD, Slavik R, Mona CE, Calais J, Rettig M, Reiter RE, Herrmann K, Radu CG, Czernin J, Eiber M. PMID: 30374743; PMCID: PMC6206308.
      View in: PubMed   Mentions: 43  
    159. Solitary Mucinous Prostate Adenocarcinoma Lung Metastasis Detected by 68Ga-PSMA-11 PET/CT. Clin Genitourin Cancer. 2019 02; 17(1):e53-e55. Polverari G, Ceci F, Allen-Auerbach M, Gupta P, Fishbein MC, Reiter RE, Lee JM, Hope TA, Carroll RM, Czernin J, Calais J. PMID: 30293922.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    160. Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer. J Nucl Med. 2018 11; 59(11):1714-1721. Calais J, Kishan AU, Cao M, Fendler WP, Eiber M, Herrmann K, Ceci F, Reiter RE, Rettig MB, Hegde JV, Shaverdian N, King CR, Steinberg ML, Czernin J, Nickols NG. PMID: 29653978; PMCID: PMC6225538.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCTClinical Trials
    161. Detection Threshold and Reproducibility of 68Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer. J Nucl Med. 2018 09; 59(9):1392-1397. Lückerath K, Stuparu AD, Wei L, Kim W, Radu CG, Mona CE, Calais J, Rettig M, Reiter RE, Czernin J, Slavik R, Herrmann K, Eiber M, Fendler WP. PMID: 29602819; PMCID: PMC6910618.
      View in: PubMed   Mentions: 13     Fields:    Translation:AnimalsCells
    162. Reply: Comparison of 68Ga-PSMA-11 and 18F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence: Prospective Trial Is on Its Way. J Nucl Med. 2018 05; 59(5):861. Calais J, Fendler WP, Herrmann K, Eiber M, Ceci F. PMID: 29496985.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    163. The Utility of PET/CT in the Planning of External Radiation Therapy for Prostate Cancer. J Nucl Med. 2018 04; 59(4):557-567. Calais J, Cao M, Nickols NG. PMID: 29301928; PMCID: PMC6910632.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    164. Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. J Nucl Med. 2018 03; 59(3):434-441. Calais J, Fendler WP, Eiber M, Gartmann J, Chu FI, Nickols NG, Reiter RE, Rettig MB, Marks LS, Ahlering TE, Huynh LM, Slavik R, Gupta P, Quon A, Allen-Auerbach MS, Czernin J, Herrmann K. PMID: 29242398; PMCID: PMC5868499.
      View in: PubMed   Mentions: 66     Fields:    Translation:Humans
    165. Comparison of 68Ga-PSMA-11 and 18F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence. J Nucl Med. 2018 05; 59(5):789-794. Calais J, Fendler WP, Herrmann K, Eiber M, Ceci F. PMID: 29242404.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    166. 68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning. J Nucl Med. 2018 02; 59(2):230-237. Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, Sandler K, Chu FI, King CR, Steinberg ML, Rauscher I, Schmidt-Hegemann NS, Poeppel T, Hetkamp P, Ceci F, Herrmann K, Fendler WP, Eiber M, Nickols NG. PMID: 29123013; PMCID: PMC5807533.
      View in: PubMed   Mentions: 100     Fields:    Translation:Humans
    167. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. J Nucl Med. 2018 03; 59(3):469-478. Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, Hope T, Reiter R, Maurer T, Weber WA, Fendler WP. PMID: 29123012.
      View in: PubMed   Mentions: 208     Fields:    Translation:Humans
    168. Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. J Nucl Med. 2017 09; 58(Suppl 2):67S-76S. Eiber M, Fendler WP, Rowe SP, Calais J, Hofman MS, Maurer T, Schwarzenboeck SM, Kratowchil C, Herrmann K, Giesel FL. PMID: 28864615.
      View in: PubMed   Mentions: 91     Fields:    Translation:HumansAnimals
    169. Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented. J Nucl Med. 2017 11; 58(11):1793-1796. Calais J, Czernin J, Eiber M, Fendler WP, Gartmann J, Heaney AP, Hendifar AE, Pisegna JR, Hecht JR, Wolin EM, Slavik R, Gupta P, Quon A, Schiepers C, Allen-Auerbach MS, Herrmann K. PMID: 28473600; PMCID: PMC5666645.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    170. 68Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study. J Nucl Med. 2017 10; 58(10):1617-1623. Fendler WP, Calais J, Allen-Auerbach M, Bluemel C, Eberhardt N, Emmett L, Gupta P, Hartenbach M, Hope TA, Okamoto S, Pfob CH, Pöppel TD, Rischpler C, Schwarzenböck S, Stebner V, Unterrainer M, Zacho HD, Maurer T, Gratzke C, Crispin A, Czernin J, Herrmann K, Eiber M. PMID: 28408531.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansCTClinical Trials
    Jeremie's Networks
    Concepts (224)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (91)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-8-gc1ed69da on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California